Natera Inc (NASDAQ:NTRA) CTO Sells $21,617.70 in Stock

Natera Inc (NASDAQ:NTRA) CTO Jonathan Sheena sold 897 shares of the stock in a transaction that occurred on Monday, March 23rd. The shares were sold at an average price of $24.10, for a total transaction of $21,617.70. Following the transaction, the chief technology officer now directly owns 246,013 shares of the company’s stock, valued at $5,928,913.30. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Jonathan Sheena also recently made the following trade(s):

  • On Tuesday, March 10th, Jonathan Sheena sold 800 shares of Natera stock. The stock was sold at an average price of $33.36, for a total transaction of $26,688.00.

NASDAQ NTRA opened at $26.09 on Thursday. The company’s 50 day moving average is $33.35 and its 200-day moving average is $35.26. Natera Inc has a 12-month low of $16.87 and a 12-month high of $41.80. The company has a debt-to-equity ratio of 0.36, a current ratio of 2.91 and a quick ratio of 2.84.

Natera (NASDAQ:NTRA) last released its quarterly earnings data on Wednesday, February 26th. The medical research company reported ($0.44) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.60) by $0.16. The company had revenue of $83.20 million during the quarter, compared to the consensus estimate of $77.84 million. Natera had a negative net margin of 41.30% and a negative return on equity of 120.68%. On average, equities analysts expect that Natera Inc will post -2.36 EPS for the current year.

Several research firms recently commented on NTRA. Zacks Investment Research downgraded Natera from a “buy” rating to a “hold” rating in a research note on Thursday, January 23rd. ValuEngine raised Natera from a “hold” rating to a “buy” rating in a research report on Wednesday, March 18th. BidaskClub lowered Natera from a “buy” rating to a “hold” rating in a research note on Wednesday, March 11th. Canaccord Genuity restated a “buy” rating and issued a $46.00 target price on shares of Natera in a research note on Thursday, March 19th. Finally, Piper Sandler upped their price target on Natera from $45.00 to $49.00 and gave the company an “overweight” rating in a research report on Thursday, February 27th. Four research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $43.00.

Hedge funds have recently modified their holdings of the business. Tower Research Capital LLC TRC purchased a new stake in shares of Natera during the third quarter worth $36,000. US Bancorp DE grew its position in shares of Natera by 80.1% in the fourth quarter. US Bancorp DE now owns 1,511 shares of the medical research company’s stock valued at $51,000 after purchasing an additional 672 shares in the last quarter. NumerixS Investment Technologies Inc purchased a new position in shares of Natera in the fourth quarter valued at $64,000. Ladenburg Thalmann Financial Services Inc. grew its position in shares of Natera by 285.0% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 1,925 shares of the medical research company’s stock valued at $65,000 after purchasing an additional 1,425 shares in the last quarter. Finally, Exchange Traded Concepts LLC bought a new stake in shares of Natera during the 4th quarter valued at $87,000. 91.88% of the stock is currently owned by institutional investors and hedge funds.

Natera Company Profile

Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.

Read More: Pattern Day Trader – What is the PDT Rule?

Insider Buying and Selling by Quarter for Natera (NASDAQ:NTRA)

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.